research PC-SPES Studies Promising, But Manufacturer Shuts Down
Promising cancer treatments were found, but the manufacturer closed.
Search
for
Sort by
Research
600-630 / 1000+ resultsresearch Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs
The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
research Re: A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Post-Finasteride Syndrome
research Selective non-steroidal inhibitors of 5α-reductase type 1
Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
research MP31-04 HOW DO 5-ALPHA-REDUCTASE INHIBITORS CHANGE PSA DENSITY IN PATIENTS ON ACTIVE SURVEILLANCE?
5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.
research Androgen receptor modulators: a review of recent patents and reports (2012-2018)
New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
research Management of Advanced Prostate Cancer Undergoing Major Shift
New treatments are making advanced prostate cancer management more complex but also more hopeful.
research 5α-Reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives
Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
research Optimizing finasteride chemoprevention
research Influencia del tratamiento con alfa bloqueantes e inhibidores de la 5 alfa reductasa en los hallazgos morfológicos e inmunohistoquímicos de la hiperplasia benigna de próstata
Finasteride treatment makes the prostate look more like a healthy one.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
research A population‐based nested case–control study: the use of 5‐alpha‐reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia
Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
research EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines
Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.
research Inhibition of rat α-reductases by finasteride: Evidence for isozyme differences in the mechanism of inhibition
Finasteride effectively blocks rat enzymes, but with varying methods and strength.
research Finasteride Inhibits Human Prostate Cancer Cell Invasion through MMP2 and MMP9 Downregulation
Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.
research Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib
Gefitinib can cause hair loss without scarring.
research Real-life Data for Tenofovir Alafenamide Fumarate Treatment of Hepatitis B: the Pythagoras Cohort
Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
research Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
Blocking certain proteins can reduce skin inflammation caused by cancer treatment.
research 5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety
Dutasteride works better than finasteride for hair loss, with both being safe to use.
research Drug News
Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
research Finasteride와 저용량 Dutasteride 병용요법으로 호전된 안드로겐성 탈모증 1예
Combining low-dose dutasteride with finasteride improved a man's hair loss.
research Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.
research Follow‐up of Adverse Drug Reactions from Peginterferon alfa‐2b—Ribavirin Therapy
Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
research The Effect of 5 -Reductase Inhibitors on Erectile Function
5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.
research New oral anticoagulants and their reversal agents
New oral anticoagulants are safer and easier to use with new reversal agents for bleeding emergencies.
research 1493 Dynamic changes in fibroblast subpopulations drives development of radiation-induced skin fibrosis through the fra/c-jun pathway
Radiation treatment causes skin fibrosis by increasing certain fibroblast subpopulations, but using a c-Jun inhibitor or fat grafting can reduce this effect.